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A PI mutation (Arg-&kLeu) was idcntkd in 21 dysfunctional Cl inhibitor from ;I pittient \viih type 1 Z hcrcdktry angioncurotic cdrma. The 
mutation was defined at the lcvol of 111~ protein (by scqucncc anulysis of rhc P,snfrb)rrorrtrs ~n’~~gi~~ost~ clnstasc-dcrivcd rcsclivc ccntcr pcptidc). i~nd 
the mRNA (CGC-ZTC) (by scqucnce ttntilysis of PCR-nmplilicd DNA). 
Cl inhibitor: Hcrcditilry nngioncurotic cdcma; Scrpin: Point niuttttion: I’liIsmti prolainasc inliibilol 
1, INTRODUCTLON 
Cl inhibitor (Cl INH) is a member of the se/*ine 
proteinase irrhibitor (serpin) superfamily. The reactive 
center egion of set-pins mimics the natural substrate of 
target proteases. The residue amino-terminal to the pep- 
tide bond recognized by target proteases is termed Pl, 
while PI’ is the residue carboxyl-terminal to this bond. 
Adjacent residues in each direction are numbered con- 
secutively. The ‘ntttmpt’ by the protease to hydrolyze 
the PI-PI’ bond is subverted by the formation of a tight 
protease-protease inhibitor complex. A primary detcr- 
minant of inhibitor specificity is the PI residue, which, 
in the case of Cl INH, is arginine. 
Dysfunction, or deficiency, ofCl INH results in here- 
ditary angioneurotic edema (HANE). The majority of 
mutations resulting in dysfunction of Cl INH (type 2 
HANE) alter the codon for the reactive center arginine 
(Pl) [l-4]. Single base changes in this codon (CGC) 
could result in six possible amino acid substitutions: 
His, Cys. Ser. Leu, Gly or Pro. Nearly all PI mutations 
thus far observed replace the At-g with His or Cys. One 
example of a PI Arg+Ser has bee!? described [4]. The 
preponderance of His and Cys substitutions is likely 
related to the increased propensity toward mutation of 
the cytosine in the CpG dinucleotide [5]. In this com- 
dhhr~virttiom: Cl IKH. C 1 inhibitor; HANE, hcrcdititry ttngiotxu- 
rotic cdcmn; PCR. polymurttsc chain reaction; TFA. trifluoroacctic 
acid: HPLC, high performance liquid chromatography: SDS-PAGE, 
sodium dodecyl sulktc poly;tcrylamide gel clcctrophorcsis. 
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munication wedescribe the analysis of dysfunctional Cl 
INH (Gu). in which the PI Arg is replaced with a Lcu 
residue. 
2. MATERIALS AND METHODS 
The patient is ;I mcmbcr of ;I kindred in which no other funlily 
members ht~vc symptoms sugycstivc of HANE. She. thcrcforc. may 
hitvc u spo~~~;~~~cous new mutution. Unfor!unirtcly. I’amily mcmbcrs 
wcrc not ;tviril;rblc for testing, so this could not bc proven form;llly. 
No diwasc-ussociaxl rrs\richon frugmcnt Icny~h polymorphism \vtls 
obscrvcd in this pnticnt [G]. 
Totul’ccllul;rr RNA Wits isohkd I-rom lllOllOcylc monoluycrs [7] us 
previously dcscribcd [8]. NILI WiIs quttntitutcd by absorb;mcc at 200 
IIIII. cUNA was synthesin~d from lhc pticnl’sa~ld norll>;ti RNA (I //g) 
with AMV rcvcrsc trttnscriptnsc (Bochringcr-Mantll~ciln Inc., India- 
napolis. IN). The cDNA \Y;LS amplilicd by PCR using litr/l DNA 
polymcrnsc (Pcrkin-Elmer Corp.. Norrr;ilk, CT; 3OsycIcs ol’dcn;ttur;t- 
tion, 94°C. 1 min; annculing/cxtctlsion 72°C. 5 min [L)]). Three sots of 
scnsc!;intiscnsc 30.base oligonuclcotidcs were synthesized (Applied 
Biosystcms nlodcl380B DNA synthcsizcr. Applied Biosystcms. FUWI 
City. CA). und wore dcsipncd to cover the cntirc Cl INH cDNA 
coding scqucncc. Ampliticd cDNA wus purilied by ugurosc ycl clcctro- 
phorcsis I’ollowcd by clcclroclulion (Intcrnu~ional l3iotcchnolopics 
Inc.. NCM’ Haxn. CT). 
Aillpilticd DNA \vils subcloncd into pUCI9 (Bochringcr- 
Mannheim Inc.) and double-strundcd DNA scqucncing WIN pcr- 
formed by the didcoxynuclcotidc chain-tcrminution method (Sc- 
qucnasc Kit: United States Biochemical Corp.. Clcvcland. OH) [IO]. 
Cl INH ws isoktcd from Gu plasmit by Icctin affinity chromtttog- 
ritphy [I I]. The isolated protcin wits digcslcd with l?scl,rhr,rtcr/lrr.u MW- 
&tsrr clast;isc (a gift of Dr. Morihuri. Kyo~o Rcscnrch Lubordlorics. 
Tokyo, Jupan) as described by Pcmbcrton ct al. [ 12]. High pcrlbrm- 
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Fig. I. Nucleotidc sequence analysis of the PCR-umplilied Gu DNA from the normal and muunl ullelcs. The sequences shown each corresponds 
to the coding strand. The protein sequcncc. thcrcforc, l’rom bollon IO lop corresponds 10 amino- IO curboxy-icrminal. The ahcrcd nuclcotides arc 
circled. and lhc rcsulling amino acids indicaud by usuxisks. 
mx liquid chrom;~~ography (HPLC) srpur;ltion 01. the P.rr~r/~/~lfrrrrr~rrs,~ 
cl;lsl;tac-dtrivcd pcplidcs WIS pcrlbrnxd ;IS dcscribcd by Auluk CL al. 
[I] using u rcvcrsc ph;~sccolun~n (Wars Dchapak C I8.300 A. 3.9 mm 
x I5 cm). Alicr smplc injcclion. ibc column was wasbcd wiU1 0.1% 
Mluoroacc~lc ncid (TFA)+% ncaoniirilc I’or IO min. l’ollowing which 
;I linear yrtidicnt to 0.1% TFA/L(OW acclonilrilc was duvclopcd: llow 
IXW Wits I ml/min. AIII~IIO uxminal scqucncc an;~lyscs or hc is&ttd 
pcplidcs \vcrc pcrlbrmcd using XII Applied Biosyslcms 177A prolcin 
scqucnccr will1 610 duia unnlysis soliworc (Foskr City. CA). 
3. RESULTS 
Sequence analysis of PCR-amplified DNA revealed 
the presence of clones that contained a single base 
change at nuclcotide 1432, as compared with the normal 
sequence (Fig. I). This G+T mutation converted the 
codon for the reactive center Arg-444 to a Leu codon. 
There were no other changes in the coding sequence of 
the mutant allele. Clones were also identified in which 
the sequences were completely normal, which is con- 
sistent with the heterozygous nature of HANE. The 
mutation was confirmed with two separate preparations 
of PCR-amplified DNA in order to diminish the possi- 
bility that the mutation was a PCR-induced artifact. 
SDS-PAGE of isolated Cl INH Gu revealed usingle 
polypeptide with an apparent M, of 105.000 (not 
shown), which was indistinguishable from the normal 
protein. HPLC separalion of the P~s~udatmmxs elastase- 
generated products revealed three peptides peaks that 
eluted between 33 and 35 min into the gradient. Normal 
Cl INH protein digested with Pscutlo~no~rus cla tase 
yielded a single peptide in this region, which resulted 
from cleavage of the peptide bond carboxy-terminal to
Scr-441 (between P3 and P4) [l,l2]. In addition, many 
Cl INH preparations contained the carboxy-terminal 
fragment resulting from cleavage between PI and Pl’. 
The first two peptidcs to elute (at 33.30 and 33.60 min, 
Fig. 2) were present in relatively low yield. The amino- 
terminal sequence of the first of these was identical to 
the sequence beginning with PI’, while the second had 
a sequence matching that of the peptide derived from 
P.seudormras elastase cleavage of the normal protein 
between P3 and P4. The third peptide revealed an 
amino-terminal Leu Followed by a sequence that 
matched the sequence beginning with Pl’. This thus 
confirms the replacement of Arg-444 with a Leu residue 
in Cl INH Gu. In addition, it appears that this substitu- 
tion results in the creation of a new site that is sus- 
ceptible to proteolysis by Pseudon~orzus elastase. This 
new site, Ala-Leu. is compatible with the known sub- 
strate specificity of Pseuiiotnorm clastase. 
4. DISCUSSION 
Seventy to seventy-five percent of dysfunctianal Cl 
INH proteins analyzed thus far have resulted from re- 
placement of’ the reactive center Arg residue [I -4,13]. 
Including the protein described here, of 32 mutant dys- 
functional proteins [ 1-4.13-l 7; Aulak, unpublished 
data) 23 had substitutions at the reactive center. Only 
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P? * Pl Pl’ PI.2 
Normal sir ala 11a 581 Val Ala Arg Thr I&u Lau Val Phe Qlu Val Gln Gin PtO Phs 
33.30 mln Thr Lou mu Val Pha Qlu Vnl Gin aln Pro 
33.60 min Val Ala Arg Thr Lou mu Val. Phm Glu Val 
34.05 min Lou Tht taru LOU Val Bhe Glu Val Qln Oln 
Fig, 2. The amino acid scqucncc ol’norm;lI C I INH in the r&n cxtcnding liom P7 to PI 2’, togcthcr with the scqucncos or the three peptides dcrivrd 
from Cl INH Ciu. The asterisk indicutrs the previously dctcrniincd site 01’ ClCtiVugU by ~,v~lrrlrrr,~r,rflrs clu tasc. 
two were residues other than His or Cys. Most non- 
re::ctive center mutant proteins resulted from mutations 
within the hinge region (residues P9-Pl4j. amino-ter- 
minal to the reactive center [13-l 5.171. 
The probable explanation for the preponderance of 
reactive center Arg+His and Cys substitutions is the 
hypermutability of the CpG dinucleotide. The Cl INH 
Arg-444 codon is CGC. The CpG dinucleotide is the 
primary methylatcd scqucncc in vertebrates, und it mu- 
tates frequently by deumination of 5-methylcytosinc to
thymine [IS]. This mechanism accounts for as much as 
35% of coding region point mutations causing human 
disease [l&20]. At Arg-444, this mutation in the coding 
strand (CGC+TGC) results in replacement with a Cys 
residue. The same mutation in the anticodin 
(GCG+GTG) results in alteration of the codon to one 
encoding a His (CAC). Of the other four possible re- 
placemenis resulting from poim mutation at the reactive 
center, Ser [4] and Lcu (ihis report) each have been 
observed once, while neither Gly liar Pro have been 
seen. Although the data remain limited, there are some 
indications thut the number of mutations <including si- 
lent point mutationsj within exon 8 (which encodes the 
reactive center and hinge region) may be greater than 
the number expected if mutations were distributed ran- 
domly through the gene [13-l 7.21.22]. There may there- 
fore be as yet undefined factors (in addition to the CpG 
dinucleotidej that predispose this region to mutalion. 
None of the reactive center mutants have significant 
activity against the normal target prokases. Arg- 
444+His mutants produced by site-directed mutation 
revealed the acquisition of inhibitory activity against 
chymotrypsin [23]. Subsequently, the naturally occur- 
ring PI His mutant was shown to form a complex with, 
and inhibit chymotrypsin [24]. The normal Cl 1NH 
protein also inhibited chymotrypsin, although less cl% 
cicntly than the His mutant. The normal protein, how- 
ever, used the PI! Ala as the reactive center raLher than 
the PI Arg, while the mutant used the PI His. Because 
chymotrypsin activity is favored by hydrophobic rcsi- 
dues in the PI position in substrates. it is possible that 
Cl INH Gu may inhibit chymotrypsin or other chymo- 
trypsin-iike proieasrs. Siudics iiiui iiiiii iiiitiij;Ze ilie iii- 
teraction of this mutant with chymotrypsin and cathcp- 
sin G are in progress. 
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